News
Sixth patient treated
A sixth patient — the third to receive the full therapeutic dose — has been treated. The primary, secondary, and exploratory endpoints…
Fifth patient treated for cancer
A fifth patient has been treated for non-muscle invasive bladder cancer with our drug TLD-1433. Consult the press release for more information.
Interim analysis of trial data: exploratory outcomes met
The interim analysis of the trial data has yielded promising results. A high level of safety, tolerability, and pharmacokinetics was demonstrated in…
A fourth patient has been successfully treated with TLD1433. Your days are numbered, bladder cancer!
Continuing the Phase Ib clinical trial, a fourth patient has now been successfully treated with our PDT technology for non-muscle invasive bladder…
Our compound TLD1433 has entered a human clinical trial! UPDATE: 3 patients treated! Six more to be enrolled in the study.
Our compound TLD1433 is in a clinical trial for non-muscle invasive bladder cancer! The primary and secondary objectives for the first three…
